Risk Factors for Early Remodelling in Severe Asthma in Children

NCT ID: NCT02806466

Last Updated: 2016-06-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 67 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-03-31
• Study Completion Date: 2015-11-30

Brief Summary

• Background: Asthma is a frequent disease characterized by bronchial hyperresponsiveness, inflammation and remodeling. Consistent epidemiological data indicate that outcome of asthma in adults may be determined in early childhood. This may be due to bronchial remodeling, an abnormal repair process that contributes to the development of poorly reversible airway narrowing. It appears very early in the natural history of the disease and involves increased mass of bronchial smooth muscle (BSM). The mechanism of such an increase has been related with an increase in smooth muscle cell proliferation. Recently, we have demonstrated that in severe asthma, BSM increased proliferation is induced by an enhanced mitochondrial biogenesis. Moreover, we have also shown that immature human, non-asthmatic airway smooth muscle cells (ASMC) proliferate to a greater extent than normal adult ASMC, in a similar fashion to adult asthmatic ASMC. Immature ASMC may thus have great potential to stimulate airway remodeling. We thus hypothesized that remodeling is an early process and certain characteristics of ASMC in severe preschool asthma may predispose such children to persistent remodeling with airway obstruction later in life.
• Purpose: To investigate prognostic factors of airway remodeling in preschool children, with special attention to ASMC proliferation (mitochondrial mass & biogenesis).
• Methods: In the initial phase of the project, 75 severe asthmatic preschool children (<5 yr) will be prospectively recruited from the "CHU de Bordeaux" and the "CHU de Toulouse" according to the "Haute Autorité de Santé" criteria. Inclusion visit will include written informed consent, asthma control evaluation, clinical examination, lung function testing (exhaled NO, plethysmography), prick tests, chest X Ray and blood sample for total IgE levels. Bronchial specimens from all subjects will be obtained by fiberoptic bronchoscopy at visit 2. Airway remodeling will be evaluated by morphological analysis. After smooth muscle mitochondria will be analyzed by electronic microscopy & immunoblotting. Comparison between the 2 groups will be performed by unpaired t tests for parametric data and x2-tests for non-parametric data. In the second phase of the project, patients will then be followed-up till the age of 7-10 yrs, when another bronchoscopy with biopsies will be performed.

Conditions

Asthma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Asthmatic children

Group Type: ACTIVE_COMPARATOR

Fiberoptic bronchoscopy

Intervention Type: PROCEDURE

Non-asthmatic children

Group Type: SHAM_COMPARATOR

Fiberoptic bronchoscopy

Intervention Type: PROCEDURE

Interventions

Fiberoptic bronchoscopy

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

Asthmatic children

• Parents (and possibly the child) who gave written informed consent.
• Affiliated with a social security scheme.
• Age from 1 to less than 5 years.
• Severe persistent asthma according to the criteria of the National Health Authority (Annex I) or NEW PROPOSED CRITERIA (adapted ATS (42)):

Major criteria (> 1) Asthma control in mild to moderate level requiring

1. A continuous or semi continuous (≥ 50% of the year) by oral corticosteroids

2. A treatment with high doses of inhaled corticosteroids (> 500 micrograms / day of Beclomethasone, or equivalent (> 400 micrograms / day of Budesonide,> 200 micrograms / day of Fluticasone) for at least 6 weeks.

And

minor criteria (> 2)

1. The need for an additional daily treatment (β2-agonists, long-acting, theophylline, anti-leukotrienes)

2. Symptoms that require taking daily or almost daily of β2-agonists of short action

3. persistent obstruction (FEV <80% PEF variability> 20%) (If reliable spirometry, usually> 5 years of age)

4. One or more seeking care in emergency / year

5. At least three short courses of oral corticosteroids / year

6. Rapid Increases caused by the decrease of 25% of the dose of oral corticosteroids or inhaled

7. ATCD of severe acute asthma who put in life-threatening

Non-asthmatic children

• Non asthmatic child with indication of endoscopy:

• Any endoscopy for a disease without acute or chronic inflammation in the biopsy area (≥1 to <5 years (1st part): congenital stridor, double aortic arch, foreign body removal inhaled, ...; ≥ 7 to ≤ 10 years ( 2nd component): inhaled foreign body removal, ...).
• Parents (and possibly the child) who gave written informed consent.
• Affiliated with a social security scheme.
• Children not asthmatic postmortem (retrospective and prospective)

• Age from 1 to under 5 (1st part) or aged 7 to 10 years (2nd part) on the death
• Died without pulmonary pathology in the sampled area
• Non asthmatic child with thoracic surgery:

• Age from 1 to under 5 (1st part) or aged 7 to 10 years (2nd part).
• Subject with pulmonary pathology, requiring thoracic surgery lobectomy, non-inflammatory in the sampled area.
• Parents (and possibly the child) who gave written informed consent.
• Affiliated with a social security scheme.

• Review of hemostasis abnormal,
• Subject with a heart condition,
• Subject is not fasted for over 6 hours.

Children without asthma:

• Non-asthmatic children with indication of endoscopy:

• asthma diagnosed by a doctor.
• exclusion period on topic compared to another protocol.
• Subject with significant co-morbidity associated with asthma not of any nature whatsoever.
• bronchial malformations (exclusion criterion ex post).
• Subject with a dental infection, or nasopharyngeal airway (viral or bacterial) with fever (> 39 ° C) in the 4 weeks preceding the survey.
• chronic viral infections (hepatitis, HIV).
• Review of hemostasis abnormal,
• Subject with a heart condition,
• Subject is not fasted for over 6 hours.
• Children postmortem non-asthmatics:

• asthma diagnosed by a doctor.
• Subject with a dental infection, or nasopharyngeal airway (viral or bacterial) with fever (> 39 ° C) within 4 weeks before sampling of tissue.
• chronic viral infections (hepatitis, HIV).
• Non-asthmatic children with thoracic surgery:

• asthma diagnosed by a doctor.
• exclusion period on topic compared to another protocol.
• Subject with a dental infection, or nasopharyngeal airway (viral or bacterial) with fever (> 39 ° C) within 4 weeks before sampling of tissue.
• chronic viral infections (hepatitis, HIV).

Exclusion Criteria

Asthmatic children:

• Subject having a severe exacerbation of asthmatic disease requiring hospitalization in the 3 weeks preceding their inclusion.
• exclusion period on topic compared to another protocol.
• Subject with significant co-morbidity associated with asthma not of any nature whatsoever
• bronchial malformations (exclusion criterion ex post).
• Subject with a dental infection, or nasopharyngeal airway (viral or bacterial) with fever (> 39 ° C) in the 4 weeks preceding the survey.
• chronic viral infections (hepatitis, HIV).

• Minimum Eligible Age: 1 Year
• Maximum Eligible Age: 5 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital, Bordeaux

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

MICHAEL FAYON, Professor

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Bordeaux

Locations

CHU de Bordeaux

Bordeaux, Aquitaine, France

Hôpital des Enfants

Toulouse, Occitanie, France

Countries

France

References

Fayon M, Beaufils F, Esteves P, Campagnac M, Maurat E, Michelet M, Siao-Him-Fa V, Lavrand F, Simon G, Begueret H, Berger P; P'tit Asthme Study Group. Bronchial Remodeling-based Latent Class Analysis Predicts Exacerbations in Severe Preschool Wheezers. Am J Respir Crit Care Med. 2023 Feb 15;207(4):416-426. doi: 10.1164/rccm.202205-0913OC.

Reference Type: DERIVED

PMID: 36108144 (View on PubMed)

Other Identifiers

CHUBX 2010/20

Identifier Type: -

Identifier Source: org_study_id